TrialPloS one2013

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.

Anita K Gandhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.